Search results
Results from the WOW.Com Content Network
A box of Plavix. Plavix is marketed worldwide in nearly 110 countries, with sales of US$6.6 billion in 2009. [45] It was the second-top-selling drug in the world in 2007 [46] and was still growing by over 20% in 2007. US sales were US$3.8 billion in 2008. [47] Before the expiry of its patent, clopidogrel was the second best-selling drug in the ...
Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors, like ticlopidine (trade name Ticlid) and clopidogrel (trade name Plavix). These agents reduce the aggregation ("clumping") of platelets by irreversibly binding to P2Y 12 receptors. Prasugrel inhibits platelet aggregation more rapidly, more consistently, and to a ...
Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. [5] By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries.
For premium support please call: 800-290-4726 more ways to reach us
A 2020 review stated that PSSD is rare, underreported, and "increasingly identified in online communities". [76] A 2024 study investigating the prevalence of persistent post-treatment genital numbness among sexual and gender minority youth found 13.2% of SSRI users between the ages 15 and 29 reporting the symptom compared to 0.9% who had used ...
In order to start selling a drug promptly after the patent on innovator drug expires, a generic company has to file its ANDA well before the patent expires. This puts the generic company at risk of being sued for patent infringement, since the act of filing the ANDA is considered "constructive infringement" of the patent. [ 41 ]
An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation [1] and inhibit thrombus formation.
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).